$5.20—Stale · unknown old
OTC • Last print unknown ago
$5.20—Stale · unknown old
9/15/26
Surgical Science Sweden (SUSRF)
Tuesday
4:23 PM
ThesisRecent contract wins and strategic partnerships are expected to drive revenue growth, improving investor sentiment.
Revenue Outlook
What’s Driving the Stock
- 01Surgical Science has secured a multi-year contract with a leading medical school, potentially increasing annual revenues by 15%.
- 02The company is developing a new VR-based training module expected to launch in Q4 2026, which could capture a new segment of the market.
- 03Recent partnerships with major medical device firms could lead to bundled offerings, enhancing market penetration.
- 04Growth in minimally invasive surgical procedures
- 05Increasing investment in medical training technologies
- 06Adoption rates of surgical simulation technology in hospitals and medical schools
- 07Regulatory approvals for new simulation products
- 08Partnerships with medical device manufacturers
FY2025 Snapshot
- Revenue
- $990M
- Rev. Growth
- +12.0%
- Gross Margin
- 58.1%
- Op. Margin
- 11.0%
- Net Margin
- 6.7%
- Net Income
- $67M
- NI Growth
- -49.4%
- EPS
- $1.29
- 1Y Return
- -50.2%
SUSRF Chart
My Notes
- "Our focus on innovative training solutions is positioning us for significant growth in the coming years."
- Moat: Surgical Science's proprietary technology and established relationships in the medical education sector provide a strong competitive moat.
- growth - Investors are likely drawn to the company's potential for revenue growth in the expanding surgical simulation market.
- Low - The company has no debt, so interest rates do not directly impact financing costs.
- Watch on earnings: Adoption rates of surgical simulators in key markets, Revenue growth in North America and Europe, Gross margin trends.
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $1.0B to $1.1B as surgical science has secured a multi-year contract with a leading medical school.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.